Operationalizing ADC Clinical Trials: Dose, Safety, and Design
Ashley Herrick
Antibody–drug conjugates (ADCs) are rapidly reshaping the oncology treatment landscape. By combining the targeting precision of monoclonal antibodies with the cytotoxic potency of small-molecule payloads, ADCs offer the promise of improved efficacy with more controlled toxicity. This potential has fueled unprecedented growth across the pipeline, with dozens of ADCs already approved and hundreds more in... The post Operationalizing ADC Clinical Trials: Dose, Safety, and Design appeared first on P